AstraZeneca Aktie News

BENSALEM, Pa. , Jan. 24, 2025 /PRNewswire/ -- The Law Offices of Howard G.

SAN FRANCISCO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shad...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you purchased or acquired securities in AstraZeneca between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi & Far...

AstraZeneca is one of the fastest-growing players among Big Pharma. The company's significant balance sheet strengthening in recent years has been driven by the rapid expansion of its portfolio of FDA-approved drugs, particularly those targeting cancer. So, one of AstraZeneca's latest achievements was the FDA's approval of Datroway on January 17, 2025, for the treatment of certain adults with b...

NEW YORK , Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

LOS ANGELES , Jan. 23, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws. Shareholders who bought the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before F...

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shad...

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.